Product Name:
Myc-pT58+pS62
Product Number:
ab-pn628
Target Full Name: Myc proto-oncogene protein
Target Alias: BHLHe39; C-Myc; C-myc; Transcription factor p64; V-myc myelocytomatosis viral oncogene; V-myc myelocytomatosis viral oncogene homolog (avian)
Product Type Specific: Myc phosphosite-specific antibody
Antibody Code: PN628
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T58+S62
Protein UniProt: P01106
Protein SigNET: Myc
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human Myc
Antibody Immunogen Sequence: ELLP(pT)PPL(pS)PSR(βA)C
Antibody Immunogen Description: Corresponds to amino acid residues E54 to R65. T58 and S62 phosphorylation induces transcriptional activation and binding to AurA, CDC73, CIP2A, DNA, FWXW7, PIN1, and SH2BP1 and Axin 2. T58 phosphorylation inhibits interaction with DNA, FBXW7 and TUBA4A. These are two of the major in vivo phosphorylation sites in mTOR (≥57 and ≥59 reports, respectively, from high throughput mass spectrometry studies recorded in PhosphoSitePlus). Myc is known to be phosphorylated in vitro at T58 by ERK2 (MAPK1), GSK3a, GSK3b, JNK3 (MAPK10), and at S62 by CDK5, ERK1 (MAPK3), ERK2 (MAPK1), JNK1 (MAPK8), JNK2 (MAPK9), JNK3 (MAPK10), mTOR (FRAP1), and Plk1.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.6 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus macaque | Rat | Mouse | Chicken | Frog | Zebra fish.
Scientific Background: Myc (Myc proto-oncogene protein) is a a 62-64 kDa nuclear phosphoprotein and transcription factor that acts as a master regulator of cell growth, proliferation, metabolism, and apoptosis. It dimerizes with its partner Max to bind E-box sequences (5'-CAC(G/A)TG-3') in DNA, and regulates up to 15% of all genes. In the absence of Max, it binds to DNA promoters with less specificity. It features a basic helix-loop-helix leucine zipper (bHLH-LZ) domain at the C-terminus, which is necessary for dimerization with Max and DNA binding. It drives cell cycle progression and is essential for rapid cell proliferation, but it also acts as a potent inducer of apoptosis (programmed cell death) when necessary. It acts mainly as a transcriptional activator (can also act as a repressor) of genes involved in metabolic pathways, mitochondrial biogenesis, and protein synthesis. It binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Beyond Max, c-Myc interacts with over 40 other proteins to mediate its complex functions. c-Myc is highly unstable, and its levels are tightly regulated by protein degradation, meaning its activity is directly related to its concentration in the nucleus. It can be an oncoprotein that is often overexpressed in over 40% of human cancers, including Burkitt's lymphoma and multiple myeloma. Deregulated c-Myc, often caused by translocation or amplification, promotes uncontrolled cell growth, angiogenesis, and tumour survival. This description may include information annotated by UniProt and/or Google AI.